Evaluate therapeutic candidates in clinically relevant ex vivo systems that preserve key features of human tissue biology, inflammatory response and donor-specific disease phenotypes.
RoukenBio’s ex vivo assay platforms are designed to help drug developers generate more translationally meaningful data earlier in discovery and preclinical development.
Understanding how a therapeutic will behave in human disease requires models that reflect the biological complexity of the systems they are designed to treat. Ex vivo approaches provide a valuable bridge between simplified preclinical assays and human disease, enabling therapeutic responses to be explored in biologically relevant human systems.
RoukenBio’s ex vivo capabilities span inflammatory disease, respiratory biology and immuno-oncology, with models designed to preserve intact tissue biology or recreate selected features of the human disease environment. Our portfolio includes patient-derived intestinal tissue models for IBD, donor-derived air-liquid interface models of the human airway, and patient-derived colorectal cancer models incorporating tumoroids, atologus tumour infiltration lymphocytes and components of the tumour microenvironment.
Explore RoukenBio’s capabilities across translational biology and drug discovery, and find the expertise and approaches to support your programme.
All patient-derived material is ethically sourced through our established clinical and biobank partners. Samples are collected with informed patient consent under appropriate ethical approvals, and are pseudonymised before they reach us. Where available, they come with relevant clinical information to help you select the right donors and interpret your results.
